Minerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Other Events

Minerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Other Events

Story continues below

Item8.01

Other Events

On January20, 2017, Minerva Neurosciences, Inc. (the Company)
issued a press release providing additional details from the
Companys Phase IIb clinical trial of MIN-101. A copy of the above
referenced press release is filed as Exhibit 99.1 to this Current
Report on Form 8-K. The Company is also filing as Exhibit 99.2 to
this Current Report on Form 8-K an updated slide to be used in
its Corporate Presentation.

Item9.01. Financial Statements and Exhibits

(d)Exhibits

Exhibit

No.

Description

99.1 Press Release of the Company dated January20, 2017
99.2 Corporate Presentation slide


About Minerva Neurosciences, Inc. (NASDAQ:NERV)

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease. MIN-101 blocks serotonin receptors and sigma receptors, over two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen Pharmaceutica NV. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 protein.

Minerva Neurosciences, Inc. (NASDAQ:NERV) Recent Trading Information

Minerva Neurosciences, Inc. (NASDAQ:NERV) closed its last trading session 00.00 at 10.50 with 149,912 shares trading hands.

An ad to help with our costs